GRPZ - ETF AI Analysis
Top Page
Invesco S&P SmallCap 600 GARP ETF (GRPZ)
Rating:72Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and over the last few months, indicating solid recent momentum.
Leading Holdings With Strong Gains
Several of the largest positions, such as Dave, Sezzle, TG Therapeutics, and Krystal Biotech, have delivered strong year-to-date gains that support the fund’s overall performance.
Broad Sector Diversification
The fund spreads its investments across many sectors, including financials, health care, technology, industrials, and consumer stocks, which helps reduce the impact of weakness in any single industry.
Negative Factors
Small Asset Base
The ETF manages a relatively small amount of assets, which can make it more vulnerable to large investor inflows or outflows and potentially less liquid than bigger funds.
Concentration in U.S. Market
Almost all of the ETF’s holdings are in U.S. companies, offering little geographic diversification if the U.S. market faces a downturn.
Mixed Performance Among Top Holdings
Some key holdings, including Inspire Medical Systems, TransMedics Group, ACADIA Pharmaceuticals, and Millrose Properties, have shown weak or negative performance this year, which can drag on overall returns.
GRPZ vs. SPDR S&P 500 ETF (SPY)
AUM3.24M
RegionNorth America
Expense Ratio0.35%
Beta0.94
IssuerInvesco
Inception DateMar 27, 2024
Dividend Yield0.87%
Asset ClassEquity
Index TrackedS&P SmallCap 600 GARP Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume811
30 Day Avg. Volume900
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
38.88Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering89
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GRPZ Summary
The Invesco S&P SmallCap 600 GARP ETF (GRPZ) is a fund that follows the S&P SmallCap 600 GARP Index, focusing on smaller U.S. companies that are growing but not considered too expensive. It spreads your money across many sectors, including financials, health care, and technology. Some of its holdings include Cal-Maine Foods and Inspire Medical Systems. An investor might choose this ETF to seek long-term growth and add diversification beyond large, well-known companies. A key risk is that small-cap stocks can be more volatile, so the ETF’s value can rise and fall more sharply than the overall market.
How much will it cost me?The Invesco S&P SmallCap 600 GARP ETF (GRPZ) has an expense ratio of 0.35%, which means you’ll pay $3.50 per year for every $1,000 invested. This cost is slightly higher than average for ETFs because it tracks a specific index with a focus on small-cap companies and uses a more selective strategy. It’s still relatively affordable compared to actively managed funds.
What would affect this ETF?GRPZ could benefit from economic growth in the U.S., as small-cap companies often thrive during periods of expansion and innovation, particularly in sectors like Industrials and Technology, which are heavily weighted in the ETF. However, rising interest rates or economic slowdowns could negatively impact small-cap stocks, as these companies may face higher borrowing costs and reduced consumer demand, especially in sectors like Consumer Cyclical and Financials. Regulatory changes or shifts in energy policies could also affect holdings like Helmerich & Payne and International Seaways in the Energy sector.
GRPZ Top 10 Holdings
GRPZ is powered by a lively mix of U.S. small caps, with health care and consumer names doing much of the heavy lifting. Inspire Medical Systems and TransMedics are rising lately, helping performance even though their year-to-date paths have been a bit bumpy. On the consumer side, Freshpet and Cal-Maine Foods are steadily adding support, while Dave and TG Therapeutics have been standout growers over the year, giving the fund extra spark. Overall, it’s a domestically focused, growth-at-a-reasonable-price story with no single stock dominating the stage.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Millrose Properties Inc Class A | 2.10% | $69.21K | $4.72B | -13.31% | ― | |
| Inspire Medical Systems | 2.08% | $68.63K | $1.78B | -34.42% | 73 Outperform | |
| Dave | 2.03% | $67.00K | $4.83B | 77.54% | 80 Outperform | |
| TransMedics Group | 1.87% | $61.81K | $3.07B | -23.08% | 77 Outperform | |
| Quinstreet | 1.81% | $59.52K | $1.09B | 22.32% | 69 Neutral | |
| Tidewater | 1.78% | $58.81K | $4.61B | 53.85% | 78 Outperform | |
| ACADIA Pharmaceuticals | 1.78% | $58.77K | $5.02B | 12.00% | 75 Outperform | |
| Palomar Holdings | 1.73% | $57.13K | $3.46B | 7.00% | 83 Outperform | |
| TG Therapeutics | 1.73% | $57.11K | $8.26B | 83.87% | 65 Neutral | |
| Cal-Maine Foods | 1.70% | $56.07K | $3.76B | -30.64% | 84 Outperform |
GRPZ Technical Analysis
Positive
―
Price Trends
32.73
Positive
31.25
Positive
29.42
Positive
Market Momentum
0.03
Positive
50.66
Neutral
56.98
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GRPZ, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 33.11, equal to the 50-day MA of 32.73, and equal to the 200-day MA of 29.42, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 50.66 is Neutral, neither overbought nor oversold. The STOCH value of 56.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRPZ.
GRPZ Peer Comparison
Comparison Results
Performance Comparison
GRPZ
Invesco S&P SmallCap 600 GARP ETF
32.94
6.09
22.68%
BKSE
BNY Mellon US Small Cap Core Equity ETF
―
―
―
AIMS
Acuitas Small Cap Active ETF
―
―
―
STXK
Strive 2000 ETF
―
―
―
RUSC
US Small Cap Equity Active ETF
―
―
―
SYZ
Lazard US Systematic Small Cap Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents